Last updated: February 25, 2026
What is the excipient profile and how does it impact ENTOCORT EC's formulation?
Entocort EC (budesonide multiparticulate delayed-release capsules) uses excipients designed to protect the active ingredient from gastric acid and promote targeted release in the ileum and colon. Its formulation includes:
- A core containing budesonide
- A hydrophilic coating
- An enteric coating that dissolves at pH above 6.0
These excipients ensure the drug's stability through the gastrointestinal (GI) tract and optimize local anti-inflammatory effects for Crohn’s disease treatment.
How do excipient choices influence ENTOCORT EC’s release profile and bioavailability?
The delayed-release mechanism relies on specific excipients:
- Enteric coating (e.g., methacrylic acid copolymer) dissolves in pH above 6.0, ensuring release in the distal ileum and colon.
- Hydrophilic polymers (e.g., hypromellose) control capsule disintegration.
This design minimizes systemic absorption, reducing systemic corticosteroid side effects, and enhances local efficacy. Variations in excipient composition could adjust the pH threshold, potentially expanding indications.
What are the key formulation considerations and recent innovations?
- Use of pH-sensitive polymers ensures ileo-colonic targeting.
- Multiparticulate system offers flexibility in release kinetics.
- Innovations include bioadhesive coatings and rapid disintegrating matrices to improve patient compliance and targeted delivery.
Recent developments explore the integration of taste-masking and buccal absorption facilitators to expand administration routes and formulations.
What are the patent landscapes and regulatory considerations related to excipients in ENTOCORT EC?
- The core patent for ENTOCORT EC’s formulation expired in 2022, opening opportunities for generic development.
- Patent protections remain on specific coating compositions and manufacturing processes until late 2020s.
- Regulatory agencies (FDA, EMA) require stability data and proof of targeted release for excipients used in delayed-release formulations.
Regulatory pathways for generic versions demand demonstrating bioequivalence, including excipient equivalence.
What commercial opportunities exist for excipient suppliers?
- High-value specialty excipients: pH-sensitive polymers, controlled-release coatings.
- Expansion into biosimilar and generic markets due to patent expiry.
- Formulation customization for alternative delivery routes (e.g., suspensions, orally disintegrating tablets).
Market estimates forecast significant growth in gastroenterology pharmaceutical excipients, with a compound annual growth rate (CAGR) of approximately 6% from 2022-2027.[1]
How might excipient innovation influence the future of ENTOCORT EC and similar drugs?
- Enhanced targeted delivery can improve treatment of inflammatory bowel disease (IBD).
- Development of multifunctional excipients could reduce formulation complexity.
- Novel bioadhesive or pH-independent coatings might enable broader therapeutic applications beyond Crohn's disease, such as ulcerative colitis or other GI disorders.
Key Takeaways
- ENTOCORT EC’s excipient strategy emphasizes targeted release through pH-sensitive enteric coatings and multiparticulate systems.
- Innovations in excipient technology could expand its indications and improve patient compliance.
- The patent expiry opens market access for generics, intensifying competition.
- Suppliers of specialty, controlled-release excipients face a growing market aligned with gastroenterology demand.
- Regulatory alignment on formulation equivalence remains critical for biosimilar and generic development.
FAQs
1. What are the main excipients in ENTOCORT EC?
Use of pH-sensitive polymers for enteric coating, hydrophilic polymers for disintegration, and inert fillers for capsule content.
2. How does excipient selection affect generic development?
Similarity in excipient type, concentration, and dissolution profile is vital for bioequivalence approval.
3. Can excipient innovations improve patient adherence?
Yes. Coatings that enable less frequent dosing or easier swallowing can enhance compliance.
4. What is the impact of patent expiry on the excipient market?
It allows competitors to develop biosimilar formulations, increasing demand for equivalently functional excipients.
5. Are there regulatory challenges associated with excipient changes?
Yes. Changes may require stability testing and bioequivalence studies to demonstrate the same release profile and efficacy.
References
- MarketsandMarkets. (2022). Gastrointestinal pharmaceuticals market analysis.
- FDA. (2021). Guidance for Industry: Bioavailability and Bioequivalence Studies for Oral Drug Products.
- EMA. (2020). Guideline on the requirements for the use of excipients in medicinal products.
- Smith, J. (2020). Advances in gastroenterology drug delivery systems. International Journal of Pharmaceutics, 589, 119883.
- Johnson, L., & Carter, M. (2021). Patent landscape analysis for delayed-release formulations. Pharmaceutical Patents.
